JPT Peptide Technologies GmbH was established in 2004 as a spin-off of Jerini AG, a Berlin based peptide drug discovery company. In 2008, JPT became a wholly owned subsidiary of BioNTech AG, Mainz (Germany), a company that develops novel immune therapy and diagnostic approaches for various cancers. JPT Peptide Technologies GmbH is a leading provider of innovative peptide-based services, and catalog products & kits, as well as a research and development partner for projects in Immunology, Proteomics and Drug Discovery. JPT's head office and production sites are located in Berlin, Germany. All of its production and services are performed in Berlin/ Germany in accordance with DIN EN ISO 9001:2015 guidelines. Together with its US-subsidiary based in Acton, near Boston, Massachusetts, JPT is serving a worldwide customer base in the pharmaceutical and biotechnology industries, as well as researchers in universities, governmental and non-profit organizations. Over the past decade, JPT has developed a portfolio of proprietary technologies and a series of unique products and services which support research efforts in proteomics, all development phases of novel vaccines or immunotherapies and peptides based drug discovery. Since 2009, JPT is actively involved in R&D partnerships and contract research projects focusing on seromarker discovery & validation, development of immune monitoring tools and diagnostics, vaccine target discovery, peptide lead identification & optimization, biomarker quantification by targeted proteomics, enzyme substrate identification & sensitivity profiling.
JPT’s interdisciplinary team of 50 experts in peptide and medicinal chemistry, bioinformatics and assay development combines scientific expertise and creativity with unique and proprietary high throughput synthesis and assay technologies. The company structure, with various but focused expertise, provides an integrated and comprehensive one-stop-source for peptide related R&D projects and enables efficient interaction structures. An experienced project management team with a track record of successful R&D projects for over more than a decade as well as a DIN ISO 9001:2015 certified Quality Management System ensures professional project execution at short cycle times.
In addition to innovative peptide related catalog products and services, JPT applies its know-how and expertise in collaborative partnerships with companies and non-profit organizations. Depending on the goals, complexity and risk of a given project, JPT offers a variety of business models that range from fee-for-service and FTE based contract research to collaborative partnerships and risk sharing project models.
Functional proteomics aims for the elucidation of the biological function of proteins or protein groups and classes on a proteome-wide level.
This includes the characterization of enzyme activities as well as protein/protein interactions and post-translational modifications at proteins. Combining our technologies and expertise, we are able to map changes in signaling pathways as a consequence of cell-treatment or changes in environmental conditions. This can be done either by the large-scale measurement of enzymatic activities of kinase, phosphatase, protease or other protein modifying enzymes or by measurement of epigenetic modifications at proteins.
We have also developed innovative ways in evaluating and presenting complex data sets which is vital for the optimal exploitation of experimental results.
Discovery or shotgun proteomics usually targets the identification of large sets of proteins in complex samples. In targeted proteomics, high selectivity quantitative assays for lower numbers of proteins are developed, e.g. MRM assays. The significance of targeted proteomics is exemplified by the fact that it was selected as Nature Method of the Year 2012.
Multiple reaction monitoring (MRM), which is one of the most frequently used targeted proteomics approaches detects precursor and product ion pairs, furnishing assays for the detection and quantitation of proteins in biological samples spiked with proteotypic peptide standards.
JPT has been providing tools for targeted proteomics for years.
SpikeTides™ are cost-effective peptides that allow high-speed SRM assay and MRM assay development and protein quantitation with almost unlimited coverage through entire proteomes. Thousands of proteotypic SpikeTides™ can be prepared economically at unmatched turnaround times (10 000 peptides per week). Absolutely quantified SpikeTides™ (SpikeTides™ TQL) use a new approach for absolute quantification that is significantly more cost effective than using traditional AAA quantified standard peptides. SpikeTides™ also enable the monitoring of cellular regulation by incorporation of post-translational modifications. See the scheme on the bottom of the page for a graphical overview on how SpikeTides™ are used in discovery and targeted proteomics experiments.
In addition, JPT offers complete proteomic studies in collaboration with its partners. Please feel free to discuss all aspects of your project with our experts.
Our Bioinformatics expertise allows for intelligent peptide library design that, in combination with our technologies, helps to solve complex problems in target discovery and validation as well as biomedical research.
JPT offers its expertise in discovery projects to define immunodominant epitopes from various antigens or proteomes as well as for the development of tailored immune monitoring tools. Our peptide pool technique takes advantage of synthetic overlapping peptides that span entire antigen sequences and provide excellent tools for the antigen specific stimulation of CD4+ and CD8+ T-cell responses in vitro. JPT's PepMix™ Peptide Pools have been used as independent readout systems to monitor clinical vaccination and immunotherapy trials and to reactivate polyclonal CD4+ and CD8+ T-cells specific for a spectrum of viral antigens for stem cell recipients in a FDA approved trial. Further, our PepTrack™ Peptide Library platform provides access to high quality peptides designed for performance in cellular assays accompanying clinical trials.
For discovery projects, JPT developed a unique and economical workflow for the proteome spanning T-cell epitope discovery using well established and commonly used T-cell assays such as ELISpot.
JPT offers a comprehensive workflow for systematic elucidation of different epitope patterns, epitope spreading and changes of B-cell immune responses against linear epitopes within an antigen, antigen family or entire proteome. Epitope patterns can be monitored in detail and correlated to disease progression, therapeutic intervention or any other clinical evidence. The investigation of samples at different time points and with secondary detection antibodies of different isotype specificity allows characterization of time dependency and involvement of different phases of the humoral immune response. In contrast to conventional assays utilizing full length proteins, peptide based technologies such as Peptide Microarray-based Profiling and Peptide ELISA provide high resolution information about the antibody repertoire in blood and other samples down to distinct linear epitopes.
Furthermore, only JPT’s synthetic peptide arrays allow representation of sequence diversity and defined posttranslational modifications.
JPT’s seroprofiling platform consists of three synergistic but independent modules as follows:
a) PepStar™ - High Content Peptide Microarrays for multiplexed biomarker discovery
b) PepStar™ - Multiwell Peptide Microarray for biomarker verification
c) Peptide ELISA for validation of detected biomarkers. The modules can be applied sequentially in milestone-driven biomarker discovery programs or individually in projects targeting the development of robust humoral immune monitoring tools in indications such as cancer, infectious and autoimmune disease as well as allergy.
Peptide optimization projects at JPT are conducted with purified compounds that are synthesized on polymeric resins or in solution. If required, proprietary high content technologies such as SPOT™ and PepStar™ support the optimization work. The process is highly iterative, taking into account all relevant optimization parameters. In this respect, we emphasize the evaluation and consideration of late-stage goals (e.g. PK/Tox properties) from early on in the optimization process (to allow early fall-back if necessary). During optimization, the lead peptides are usually converted into smaller and less peptide-like compounds (i.e. by the incorporation of unnatural amino acids, small molecule building blocks or steric constraints).
Lead optimization projects are not limited to the area of drug discovery. Our expertise is employed in many other areas of biomedical research as well as the nutritional and cosmetic industry. Exemplarily, JPT’s scientists have a profound experience in the development of specific peptidic affinity ligands for the purification of therapeutic proteins.
At JPT, we pay particular attention to the thorough qualification of hits. For this, hits are resynthesized, purified and characterized in multiple assays that are relevant to the target parameters/properties. Along with SAR analyses, profiling results enable a clear prioritization and selection of the most promising leads for optimization.
JPT has been engaged in several hit qualification / hit-to-lead projects, where hits for kinases, proteases, transferases, isomerases and phosphatases were transferred into qualified leads. The projects were done inhouse or during perennial collaborations with industry partners.
The hit qualification process at JPT is supported by an established network of service providers which addresses basically all properties relevant to drug discovery and other applications.
Over the past decade, JPT has run several successful projects for the identification of peptide hits. Among them were specific substrates for orphan proteases, kinases, phosphatases and acetyltransferases. The key to most of these screening projects was the applications of JPT's proprietary PepSpot™ or PepStar™ technologies. The respective screening libraries were designed either knowledge-based or starting from randomized sequences.
In collaboration with Bayer AG, Germany, a high content peptide library was created for screening of undisclosed targets. Overall, several million compounds were selected, synthesized and screened.
Custom Peptide Synthesis
JPT Peptide Technologies has a substantial, long-standing expertise in custom peptide synthesis services, providing custom peptides with highest quality for even complex or unusual peptide sequences. If you would like to order a quality peptide synthesis service using regulated processes, choose JPT!
Furthermore, our peptide synthesis service has a very high success rate (over 99%) as JPT has developed the know-how to choose and optimize the appropriate synthesis method for each peptide. We go the extra mile to get your peptides done!
Custom Peptide Synthesis Service
Our tailored peptides are manufactured on demand in dedicated peptide synthesis and peptide purification labs with state of the art equipment as well as highest environmental and health standards. Our customer support is happy to help with the selection of the most appropriate peptide specification for your application including peptide purity (from crude to 98%) and amount, peptide modifications and analytical options.
Custom Peptide Synthesis QC
Each peptide is routinely analyzed by LC-MS, MALDI-MS or HPLC to confirm the identity and quality of your custom peptide. Optional peptide analyses include AAA (amino acid analysis), NMR (nuclear magnetic resonance), UHPLC (Ultra-HPLC), residual solvent and water determination, solubility or stability testing and many more. For further QC/QA options in clinical applications and custom peptide synthesis under GxP conditions please check our GxP Peptides & Pools page.
Custom Synthesis of Special Peptides
JPT also has vast experience in designing and producing tailored peptides with modifications such as fluorescence labels, biotinylation, alkylation, glycosylation, phosphorylation and much more. For detailed information on peptide synthesis of modified peptides please visit our Specialty Peptides page.
"Crude peptides for great price - great for method development!"
JPT Peptide Technologies GmbH has not received any endorsements.